MX2019007642A - Anticuerpos anti-il-5. - Google Patents

Anticuerpos anti-il-5.

Info

Publication number
MX2019007642A
MX2019007642A MX2019007642A MX2019007642A MX2019007642A MX 2019007642 A MX2019007642 A MX 2019007642A MX 2019007642 A MX2019007642 A MX 2019007642A MX 2019007642 A MX2019007642 A MX 2019007642A MX 2019007642 A MX2019007642 A MX 2019007642A
Authority
MX
Mexico
Prior art keywords
human
antibody molecules
antibodies
bind
disclosed
Prior art date
Application number
MX2019007642A
Other languages
English (en)
Inventor
Clarke Adam
Doyle Anthony
Jose Simon Laine David
Terence Liddament Mark
Ann Cooksey Bridget
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2019007642A publication Critical patent/MX2019007642A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se describen moléculas de anticuerpos completamente humanos que se unen inmunoespecíficamente a IL-5 humana. Las moléculas de anticuerpo pueden unirse a IL-5 humana con una constante de afinidad de equilibrio (KD) de al menos aproximadamente 40 pM según lo determinado por la resonancia de plasmón de superficie.
MX2019007642A 2016-12-23 2017-12-20 Anticuerpos anti-il-5. MX2019007642A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662438502P 2016-12-23 2016-12-23
PCT/US2017/067475 WO2018119016A1 (en) 2016-12-23 2017-12-20 Anti-il-5 antibodies

Publications (1)

Publication Number Publication Date
MX2019007642A true MX2019007642A (es) 2019-09-09

Family

ID=60972458

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007642A MX2019007642A (es) 2016-12-23 2017-12-20 Anticuerpos anti-il-5.

Country Status (19)

Country Link
US (2) US11111292B2 (es)
EP (1) EP3559030B1 (es)
JP (1) JP7060906B2 (es)
KR (1) KR102651290B1 (es)
CN (1) CN110267986B (es)
AR (1) AR110564A1 (es)
AU (1) AU2017379853A1 (es)
BR (1) BR112019012929A2 (es)
CA (1) CA3048186A1 (es)
CL (1) CL2019001730A1 (es)
EA (1) EA201991552A1 (es)
IL (1) IL267271A (es)
MX (1) MX2019007642A (es)
NZ (1) NZ754606A (es)
PE (1) PE20191662A1 (es)
PH (1) PH12019501452A1 (es)
RU (1) RU2758008C2 (es)
WO (1) WO2018119016A1 (es)
ZA (1) ZA201904097B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630824A1 (en) 2017-05-26 2020-04-08 GlaxoSmithKline Intellectual Property Development Ltd Biopharmaceutical compositions and related methods
EP3896085A4 (en) * 2018-12-12 2022-11-30 Shanghai Pharmaexplorer Co., Ltd. MONOCLONAL ANTIBODY TO HUMAN INTERLEUKIN 5 (IL-5) AND ITS USE
KR20210145187A (ko) 2019-03-29 2021-12-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도
CN112745389B (zh) * 2019-10-29 2022-11-25 瑞阳(苏州)生物科技有限公司 结合人il-5的单克隆抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US6129913A (en) 1994-12-23 2000-10-10 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
DK1527100T3 (da) * 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
EP2231904B1 (en) 2007-12-19 2016-01-13 Janssen Biotech, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
TWI750133B (zh) 2015-08-24 2021-12-21 美商葛蘭素史密斯克萊有限責任公司 生藥組成物

Also Published As

Publication number Publication date
CN110267986B (zh) 2023-05-09
JP2020513761A (ja) 2020-05-21
RU2019123112A (ru) 2021-01-26
BR112019012929A2 (pt) 2019-12-10
CL2019001730A1 (es) 2019-09-27
EP3559030A1 (en) 2019-10-30
ZA201904097B (en) 2023-12-20
EP3559030B1 (en) 2024-04-03
EP3559030C0 (en) 2024-04-03
EA201991552A1 (ru) 2020-01-09
WO2018119016A1 (en) 2018-06-28
CN110267986A (zh) 2019-09-20
JP7060906B2 (ja) 2022-04-27
KR20190126769A (ko) 2019-11-12
RU2019123112A3 (es) 2021-04-05
RU2758008C2 (ru) 2021-10-25
PE20191662A1 (es) 2019-11-11
KR102651290B1 (ko) 2024-03-25
NZ754606A (en) 2023-06-30
AU2017379853A1 (en) 2019-07-04
US20210355205A1 (en) 2021-11-18
AR110564A1 (es) 2019-04-10
CA3048186A1 (en) 2018-06-28
US11111292B2 (en) 2021-09-07
IL267271A (en) 2019-08-29
US20180186873A1 (en) 2018-07-05
PH12019501452A1 (en) 2020-06-15

Similar Documents

Publication Publication Date Title
ZA201904097B (en) Anti-il-5 antibodies
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
PH12017502222A1 (en) Lag-3-binding molecules and methods of use thereof
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA201890143A2 (ru) Антитела против pdgfr-бета и их применения
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
MX2020009260A (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenerativos.
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201791393A2 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
EA201691027A1 (ru) Модуляторы aplnr и их применение
EA201591716A1 (ru) Антитела анти-il-33 и их применение
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
MX367661B (es) Anticuerpos anti-baff novedosos.
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201891724A1 (ru) Антитела к tgf-бета2
EA201892440A1 (ru) Антитела к tl1a и их применения
PH12018500131A1 (en) Il22 immunoconjugates
MX2015016054A (es) Terapia de combinacion anti-quimiocina del ligando 2 del motif c-c y anti-lisil oxidasa-tipo 2 para el tratamiento de escleroderma.
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EA201790437A1 (ru) Антигенсвязывающие белки, связывающиеся с cxcr3
WO2015051079A3 (en) Phosphohistidine mimetics and antibodies to same
EA201891594A1 (ru) Антитела к il-17c